Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium
Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives. Patients and methods. Endometrial biopsies from 104 premenopausal patients with...
Gespeichert in:
Veröffentlicht in: | Gynecological endocrinology 2005-07, Vol.21 (1), p.57-61 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 61 |
---|---|
container_issue | 1 |
container_start_page | 57 |
container_title | Gynecological endocrinology |
container_volume | 21 |
creator | Maia, Jr, Hugo Maltez, Amélia Studard, Eduardo Zausner, Bela Athayde, Célia Coutinho, Elsimar |
description | Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives.
Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives.
Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low.
Conclusion. The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding. |
doi_str_mv | 10.1080/09513590500099602 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16048803</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>882945001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</originalsourceid><addsrcrecordid>eNp9kU9P3DAQxa2qVVloP0AvKOqBW2BsJ04sekGrBSoh9QJny-uMd4MSe7Ed2P32ZP9IbamoD2NZ7_eexjOEfKNwTqGGC5Al5aWEEgCkFMA-kAktKp5DJcRHMtnq-RY4IscxPgJQXlTsMzmiAoq6Bj4hi5m1aFLmbZaWmPXoYgqD7jKzMR1m2jWZD9undylog6vUPmPMvNsB3q83C3Q6Ys4yXK8CxtiOWut2aega32MK7dB_IZ-s7iJ-Pdwn5OF6dj-9ze9-3fycXt3lpihFykuuK21NIySaueSlqbBmvOGGMyO4KUEgw4Lq8RiGaK0cC2tQSphTpJKfkLN97ir4pwFjUn0bDXadduiHqEQNNa0FG8Hvb8BHPwQ39qaorApWQl2NEN1DJvgYA1q1Cm2vw0ZRUNsVqH9WMHpOD8HDvMfmt-Mw8xH4sQdaZ33o9YsPXaOS3nQ-2KCdaaPi_8u__Mu-RN2lpdEB__jBu-5Xbqaodg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197425087</pqid></control><display><type>article</type><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><source>Taylor & Francis:Master (3349 titles)</source><source>MEDLINE</source><creator>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</creator><creatorcontrib>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</creatorcontrib><description>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives.
Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives.
Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low.
Conclusion. The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.1080/09513590500099602</identifier><identifier>PMID: 16048803</identifier><identifier>CODEN: GYENER</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Contraceptives, Oral - pharmacology ; COX-2 ; Cyclooxygenase 2 - analysis ; Endometrium - enzymology ; Epithelium - enzymology ; Female ; gestodene ; Humans ; Ki-67 ; Ki-67 Antigen - analysis ; Luteal Phase - physiology ; Menstrual Cycle - physiology ; menstruation ; Middle Aged ; Premenopause ; prostaglandins</subject><ispartof>Gynecological endocrinology, 2005-07, Vol.21 (1), p.57-61</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><rights>Copyright CRC Press Jul 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</citedby><cites>FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09513590500099602$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09513590500099602$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16048803$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maia, Jr, Hugo</creatorcontrib><creatorcontrib>Maltez, Amélia</creatorcontrib><creatorcontrib>Studard, Eduardo</creatorcontrib><creatorcontrib>Zausner, Bela</creatorcontrib><creatorcontrib>Athayde, Célia</creatorcontrib><creatorcontrib>Coutinho, Elsimar</creatorcontrib><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives.
Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives.
Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low.
Conclusion. The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</description><subject>Adult</subject><subject>Contraceptives, Oral - pharmacology</subject><subject>COX-2</subject><subject>Cyclooxygenase 2 - analysis</subject><subject>Endometrium - enzymology</subject><subject>Epithelium - enzymology</subject><subject>Female</subject><subject>gestodene</subject><subject>Humans</subject><subject>Ki-67</subject><subject>Ki-67 Antigen - analysis</subject><subject>Luteal Phase - physiology</subject><subject>Menstrual Cycle - physiology</subject><subject>menstruation</subject><subject>Middle Aged</subject><subject>Premenopause</subject><subject>prostaglandins</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9P3DAQxa2qVVloP0AvKOqBW2BsJ04sekGrBSoh9QJny-uMd4MSe7Ed2P32ZP9IbamoD2NZ7_eexjOEfKNwTqGGC5Al5aWEEgCkFMA-kAktKp5DJcRHMtnq-RY4IscxPgJQXlTsMzmiAoq6Bj4hi5m1aFLmbZaWmPXoYgqD7jKzMR1m2jWZD9undylog6vUPmPMvNsB3q83C3Q6Ys4yXK8CxtiOWut2aega32MK7dB_IZ-s7iJ-Pdwn5OF6dj-9ze9-3fycXt3lpihFykuuK21NIySaueSlqbBmvOGGMyO4KUEgw4Lq8RiGaK0cC2tQSphTpJKfkLN97ir4pwFjUn0bDXadduiHqEQNNa0FG8Hvb8BHPwQ39qaorApWQl2NEN1DJvgYA1q1Cm2vw0ZRUNsVqH9WMHpOD8HDvMfmt-Mw8xH4sQdaZ33o9YsPXaOS3nQ-2KCdaaPi_8u__Mu-RN2lpdEB__jBu-5Xbqaodg</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Maia, Jr, Hugo</creator><creator>Maltez, Amélia</creator><creator>Studard, Eduardo</creator><creator>Zausner, Bela</creator><creator>Athayde, Célia</creator><creator>Coutinho, Elsimar</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</title><author>Maia, Jr, Hugo ; Maltez, Amélia ; Studard, Eduardo ; Zausner, Bela ; Athayde, Célia ; Coutinho, Elsimar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-53a7afcd69ecb935c7e823d3c32c63c506e2e41aaaac2eeff9eef2de990b1e193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Contraceptives, Oral - pharmacology</topic><topic>COX-2</topic><topic>Cyclooxygenase 2 - analysis</topic><topic>Endometrium - enzymology</topic><topic>Epithelium - enzymology</topic><topic>Female</topic><topic>gestodene</topic><topic>Humans</topic><topic>Ki-67</topic><topic>Ki-67 Antigen - analysis</topic><topic>Luteal Phase - physiology</topic><topic>Menstrual Cycle - physiology</topic><topic>menstruation</topic><topic>Middle Aged</topic><topic>Premenopause</topic><topic>prostaglandins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maia, Jr, Hugo</creatorcontrib><creatorcontrib>Maltez, Amélia</creatorcontrib><creatorcontrib>Studard, Eduardo</creatorcontrib><creatorcontrib>Zausner, Bela</creatorcontrib><creatorcontrib>Athayde, Célia</creatorcontrib><creatorcontrib>Coutinho, Elsimar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maia, Jr, Hugo</au><au>Maltez, Amélia</au><au>Studard, Eduardo</au><au>Zausner, Bela</au><au>Athayde, Célia</au><au>Coutinho, Elsimar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>21</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><coden>GYENER</coden><abstract>Objective. To compare the expression of cyclooxygenase-2 (COX-2) and proliferation markers (Ki-67) in the endometrium of patients with ovulatory cycles with those in the endometrium of patients using oral contraceptives.
Patients and methods. Endometrial biopsies from 104 premenopausal patients with regular ovulatory cycles (n = 90) or using an oral contraceptive (n = 14) were selected for this study. Using immunohistochemical methods, both COX-2 (Novocastra clone 4H12) and Ki-67 (Dako clone MIB-1) expression were determined in the endometrium during the various phases of the menstrual cycle or following the use of oral contraceptives.
Results. COX-2 expression in the glandular epithelium was maximal during menstruation, the late proliferative phase and the early luteal phase, and minimal during the late luteal phase. However, in the surface epithelium, COX-2 expression remained strongly positive throughout the luteal phase. Ki-67 positivity increased during the proliferative phase and diminished during the luteal phase in the glands. In contraceptive users, both Ki-67 and COX-2 expression in the endometrium was low.
Conclusion. The increased expression of COX-2 during menstruation and at mid-cycle is eliminated by the continuous use of oral contraceptives. This may be the rationale for their therapeutic action in the treatment of dysmenorrhea and bleeding.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16048803</pmid><doi>10.1080/09513590500099602</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0951-3590 |
ispartof | Gynecological endocrinology, 2005-07, Vol.21 (1), p.57-61 |
issn | 0951-3590 1473-0766 |
language | eng |
recordid | cdi_pubmed_primary_16048803 |
source | Taylor & Francis:Master (3349 titles); MEDLINE |
subjects | Adult Contraceptives, Oral - pharmacology COX-2 Cyclooxygenase 2 - analysis Endometrium - enzymology Epithelium - enzymology Female gestodene Humans Ki-67 Ki-67 Antigen - analysis Luteal Phase - physiology Menstrual Cycle - physiology menstruation Middle Aged Premenopause prostaglandins |
title | Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A26%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20menstrual%20cycle%20and%20oral%20contraceptives%20on%20cyclooxygenase-2%20expression%20in%20the%20endometrium&rft.jtitle=Gynecological%20endocrinology&rft.au=Maia,%20Jr,%20Hugo&rft.date=2005-07-01&rft.volume=21&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0951-3590&rft.eissn=1473-0766&rft.coden=GYENER&rft_id=info:doi/10.1080/09513590500099602&rft_dat=%3Cproquest_pubme%3E882945001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197425087&rft_id=info:pmid/16048803&rfr_iscdi=true |